Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01401465 · ClinicalTrials.gov registry record · Phase 3
Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 327
- Enrollment target
NCT01401465 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 327 participants.
The verdict
NCT01401465, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 327 participants
- Enrollment target
Study Summary
This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, developed and validated to measure patient satisfaction with and preference of intranasal corticosteroids (INCS) for the treatment of allergic rhinitis (AR), is utilized in this study.
Interventions
- DRUG ciclesonide
- DRUG mometasone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 327 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01401465
The ClinicalTrials.gov registry entry for NCT01401465 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 327 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ciclesonide is the first listed.
NCT01401465 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01401465 about?
NCT01401465 is a clinical study titled "Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal Spray". This is a randomized, multicenter, 2-way crossover study in subjects 12 years or older with perennial allergic rhinitis (PAR) to evaluate patient preference, satisfaction and efficacy of ciclesonide nasal aerosol versus mometasone aqueous nasal spray. A novel patient-administered assessment, develop...
What is the current status of trial NCT01401465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 327 participants. The study started on 2011-07. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01401465?
The interventions under investigation include: ciclesonide (DRUG), mometasone (DRUG).
Who is sponsoring clinical trial NCT01401465?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.